title: Cardiac side effects of targeted therapies.
abstract: OBJECTIVE
  To review common cardiac side effects, their clinical presentation, and recommendations for assessment and management of patients receiving molecularly targeted cancer therapies.
  
  
  METHODS
  Peer-reviewed literature.
  
  
  CONCLUSIONS
  Although there is no established guideline for pretreatment cardiac evaluation and monitoring of patients receiving molecularly targeted agents, data currently supports the need for early risk identification and prevention/reduction strategies.
  
  
  CONCLUSIONS
  As nurses, we have a unique opportunity to help improve and maintain the quality of life of cancer survivors. Cardiovascular assessment and prevention/reduction strategies are essential to reduce risk of cardiovascular disease, promote optimal quality of life, and improve survival outcomes in patients receiving molecularly targeted cancer treatment.
authors.forename: Jessica
authors.initials: J
authors.lastname: Shank Coviello
mesh_terms: D006321:Heart / Q000187:drug effects*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life
keywords: Cardiotoxicity; cardiovascular assessment; targeted therapy